Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116324 · ClinicalTrials.gov registry record · Phase 3
Predicting the Response to Montelukast by Genetic Variation in Asthmatics
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT00116324 is a Phase 3 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 150 participants.
The verdict
NCT00116324, a Phase 3 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to examine a specific variation in the genetic code for an enzyme (LTC4 synthase) which plays an important role in the airway inflammation associated with asthma. We hypothesize that asthmatic patients with this variant gene will have a better response to montelukast than patients with the wild type gene, as measured by the ability of montelukast to protect against a hypertonic saline challenge.
Interventions
- DRUG Montelukast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-04 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116324
The ClinicalTrials.gov registry entry for NCT00116324 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Montelukast is the first listed.
NCT00116324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116324 about?
NCT00116324 is a clinical study titled "Predicting the Response to Montelukast by Genetic Variation in Asthmatics". The purpose of this study is to examine a specific variation in the genetic code for an enzyme (LTC4 synthase) which plays an important role in the airway inflammation associated with asthma. We hypothesize that asthmatic patients with this variant gene will have a better response to montelukast tha...
What is the current status of trial NCT00116324?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2003-04. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00116324?
The interventions under investigation include: Montelukast (DRUG).
Who is sponsoring clinical trial NCT00116324?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.